REG - Diaceutics PLC - Issue of Share Options/PDMR Shareholdings
29/07/2024 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240729:nRSc1122Ya&default-theme=true
RNS Number : 1122Y Diaceutics PLC 29 July 2024
Diaceutics PLC
Issue of Share Options/PDMR Shareholdings
Belfast and London, 29 July 2024- Diaceutics PLC (AIM: DXRX), a leading
technology and solutions provider to the pharma and biotech industry,
announces the issue of 1,494,051 share options over ordinary shares of £0.002
each in the Company ("Share Options") to certain directors, members of the
Company's senior management team and other key staff, pursuant to the
Company's Employee Share Option Plan ("ESOP") on 23 July 2024. These awards
are made in accordance with the Company's long term incentive plan as detailed
in the Company's Annual Report.
Share Options were granted as to PDMRs follows:
Name Number of Share Options granted Total no. of ordinary shares under option post grant % of existing issued share capital Effective Grant date
Ryan Keeling, CEO 236,250 581,947 0.69% 23 July 2024
Nick Roberts, CFO 168,750 327,622 0.39% 23 July 2024
Julie Browne, COO and PDMR 76,631 245,678 0.29% 23 July 2024
Jordan Clark, CDO and PDMR 74,502 190,242 0.22% 23 July 2024
Susanne Munksted, CPO and PDMR 74,647 284,829 0.34% 23 July 2024
Jillian Beggs, CCO and PDMR 72,844 129,548 0.15% 23 July 2024
A further 790,927 Share Options were granted to a total of 53 other employees.
The Share Options vest on a sliding scale up to 100%, after three years from
the date of grant (the "Performance Period"), subject to the satisfaction of
certain performance criteria. The performance criteria are based upon the
growth during the Performance Period in Total Shareholder Return ("TSR"), the
revenue Compound Annual Growth Rate ("CAGR") and recurring revenue. The
average mid-market closing share price in the three days prior to the issue of
the Share Options was £1.33. The exercise price of the Share Options is
£0.002 per share which equates to the nominal value of the ordinary shares.
Following this grant, the total number of share options outstanding in the
Company is 4,711,454 representing approximately 5.56% of its current issued
share capital of 84,720,076.
Enquiries:
Diaceutics PLC
Nick Roberts, Chief Financial Officer Tel: +44 (0)28 9040 6500
investorrelations@diaceutics.com (mailto:investorrelations@diaceutics.com)
Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710 7600
Ben Maddison
Nick Harland
Kate Hanshaw
Alma Strategic Communications Tel: +44(0)20 3405 0205
Caroline Forde, diaceutics@almastrategic.com
Kinvara Verdon
Kieran Breheny
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome.
We provide the world's leading pharma and biotech companies with an end-to-end
commercialisation solution for precision medicines through data analytics,
scientific and advisory services enabled by our platform DXRX - The
Diagnostics Network ®.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Ryan Keeling
2 Reason for notification
a. Position/Status Chief Executive Officer
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Options over new ordinary shares of 0.2p each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Grant of share options
c. Price(s) and volume(s)
Price(s) Volume(s)
Exercise price of 0.2p per share 236,250
e. Date of the transaction 23 July 2024
f. Place of the transaction Outside a trading venue
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Nick Roberts
2 Reason for notification
a. Position/Status Chief Finance Officer
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Options over new ordinary shares of 0.2p each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Grant of share options
c. Price(s) and volume(s)
Price(s) Volume(s)
Exercise price of 0.2p per share 168,750
e. Date of the transaction 23 July 2024
f. Place of the transaction Outside a trading venue
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Julie Browne
2 Reason for notification
a. Position/Status Chief Operations Officer
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Options over new ordinary shares of 0.2p each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Grant of share options
c. Price(s) and volume(s)
Price(s) Volume(s)
Exercise price of 0.2p per share 76,631
e. Date of the transaction 23 July 2024
f. Place of the transaction Outside a trading venue
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Jordan Clark
2 Reason for notification
a. Position/Status Chief Data Officer
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Options over new ordinary shares of 0.2p each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Grant of share options
c. Price(s) and volume(s)
Price(s) Volume(s)
Exercise price of 0.2p per share 74,502
e. Date of the transaction 23 July 2024
f. Place of the transaction Outside a trading venue
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Susanne Munksted
2 Reason for notification
a. Position/Status Chief Precision Medicine Officer
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Options over new ordinary shares of 0.2p each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Grant of share options
c. Price(s) and volume(s)
Price(s) Volume(s)
Exercise price of 0.2p per share 74,647
e. Date of the transaction 23 July 2024
f. Place of the transaction Outside a trading venue
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Jillian Beggs
2 Reason for notification
a. Position/Status Chief Commercial Officer
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Options over new ordinary shares of 0.2p each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Grant of share options
c. Price(s) and volume(s)
Price(s) Volume(s)
Exercise price of 0.2p per share 72,844
e. Date of the transaction 23 July 2024
f. Place of the transaction Outside a trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHBVLLLZDLBBBDRecent news on Diaceutics
See all newsREG - Diaceutics PLC - PDMR Shareholding/Share Incentive Plan and TVR
AnnouncementREG - Diaceutics PLC - Notice of Results
AnnouncementREG - Diaceutics PLC - Block Listing Return
AnnouncementREG - Diaceutics PLC - PDMR Shareholding/Share Incentive Plan and TVR
AnnouncementREG - Diaceutics PLC - PMx Promotional Partner Contract Enhancement
Announcement